DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)

Information source: Chong Kun Dang Pharmaceutical
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: CKD-330 8/5mg (Drug); Candesartan 8mg and Amlodipine 5mg (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Chong Kun Dang Pharmaceutical

Official(s) and/or principal investigator(s):
Jang Hee Hong, Principal Investigator, Affiliation: Chungnam National University Hospital

Summary

The purpose of this study is to compare the safety and pharmacokinetics of CKD-330 (fixed-dose combination of Candesartan 8 mg and Amlodipine 5 mg) with coadministration of the two separate drugs in healthy male volunteers.

Clinical Details

Official title: A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

AUCt

Cmax

Secondary outcome:

AUCinf

tmax

t1/2β

CL/F

Eligibility

Minimum age: 20 Years. Maximum age: 45 Years. Gender(s): Male.

Criteria:

Inclusion Criteria: 1. Healthy male volunteer in the age between 20 and 45 years old. 2. Body weight ≥ 55 kg and Body weight in the range of calculated IBW ±20%. 3. Subjects without a hereditary problems and chronic disease. 4. Subjects whose clinical laboratory test values are inside the accepted normal range. 5. Understand the requirements of the study and voluntarily consent to participate in the study. Exclusion Criteria: 1. Previous history or present of clinically significant hepatobiliary, nephrological, neurologic, respiratory, hemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system. 2. History of gastrointestinal disease or gastrointestinal surgery to affect drug absorption. 3. History of clinically significant allergies of amlodipine or candesartan or CCB or ARB or aspirin or antibiotic. 4. Subjects with galactose intolerance. 5. SBP ≥ 140 mmHg or< 90 mmHg, DBP ≥ 95 mmHg or < 60 mmHg, pulse ≥ 100 BPM. 6. AST or ALT > 2*ULN, total bilirubin > 2*ULN 7. Serum Creatinine > ULN 8. Previous history or present of drug abuse. 9. Subjects treated metabolizing enzyme inducers or inhibitors such as barbitals within 1 month prior to the first dosing. 10. Subjects treated ethical drug or herbal medicine within 2 weeks, OTC or vitamin within 1 week prior to the first dosing. 11. Subjects treated IP within 2 months prior to the first dosing. 12. Subjects with whole blood donation within 2 months or component blood donation within 1 month or blood transfusion within 1 month prior to the first dosing. 13. Alcohol > 21 units/week or cannot stop drinking. 14. Cigarette > 10 cigarettes/day. 15. Subjects with the plan dental treatment(extraction, orthodontic, nerve treatment) or

any surgery(plastic surgery, eye surgery - LASIK, LASEK).

16. Not eligible to participate for the study at the discretion of investigator.

Locations and Contacts

Chungnam National University Hospital, Daejeon, Chungcheongbuk-do 301-721, Korea, Republic of
Additional Information

Starting date: July 2014
Last updated: November 27, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017